MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders. |
On December 21, 2016, MYOS RENS Technology Inc. (the
Company) held its 2016 annual meeting of
stockholders (the Meeting). At the Meeting,
stockholders (i) elected three directors to serve as Class III
directors on the Companys board of directors
(Board) until the 2019 annual meeting of
stockholders or until their successors are elected and qualified,
(ii) approved the compensation of the Companys named executive
officers for 2015, (iii) approved an amendment to the Companys
2012 Equity Incentive Plan (the Plan) to
increase the aggregate number of shares of common stock which may
be issued under the Plan by 300,000 shares to 850,000 shares and
(iv) ratified the selection by the Board of Withum Smith Brown,
PC (Withum) to serve as the Companys independent
registered public accounting firm for the year ending December
31, 2016.
Set forth below are the final voting results for each of the
proposals:
Proposal No. 1 Election of directors
Joseph Mannello, Victor Mandel and John Nosta were elected to
serve as Class III directors. The voting results were as follows:
| Name | For | Withheld | ||||||
| Joseph Mannello | 1,751,869 | 1,533,183 | ||||||
| Victor Mandel | 1,762,902 | 1,522,150 | ||||||
| John Nosta | 1,762,902 | 1,522,150 | ||||||
Proposal No.2 Advisory vote regarding the approval of
compensation paid to named executive officers in
2015
The compensation paid to the Companys named executive officers in
2015 was approved, on an advisory basis. The voting results were
as follows:
| For | Against | Abstentions | ||
| 1,747,308 | 10,475 | 1,527,269 |
Proposal No. 3 Amendment of the Plan
The amendment to the Plan to increase the aggregate number of
shares of common stock which may be issued under the Plan by
300,000 shares to 850,000 shares was approved. The voting results
were as follows:
| For | Against | Abstentions | ||
| 1,652,938 | 1,622,470 | 9,644 |
Proposal No. 4 Ratification of independent registered
public accounting firm
The stockholders ratified the selection of Withum to serve as the
Companys independent registered public accounting firm for the
year ending December 31, 2016. The voting results were as
follows:
| For | Against | Abstentions | ||
| 3,375,880 |
About MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS)
MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement. MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Recent Trading Information
MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) closed its last trading session down -0.05 at 1.33 with 34,961 shares trading hands.
